Snapshot
Guardant Health, Inc. reported $281M of revenue in Q4 2025, up 39.4% year over year, with diluted EPS of $-1.00 and an operating margin of -43.0%.
- Revenue
- $281M
- YoY growth
- +39.4%
- Diluted EPS
- $-1.00
- Operating margin
- -43.0%
$281M
Revenue
+39.4%
YoY growth
$-1.00
Diluted EPS
-43.0%
Operating margin
01 Key takeaways
What management said
- •2025 represents the first full year for Shield IVD, where very meaningful volume and revenue generation exceeds our expectations.
- •We have significantly expanded the commercial team and established impactful strategic partnerships to meet the growing demand for a high-performing, blood-based screening option.
- •Importantly, this execution has directly driven strong financial performance, both accelerating our top-line growth and strengthening our path to profitability.
- •Turning to top-line performance on slide four, we delivered $281 million of revenue in the Q4, representing 39% year-over-year growth, and $982 million of revenue or 33% year-over-year growth for the full year.
- •This exceptional performance reflects continued broad-based growth across our oncology screening and biopharma and data businesses.
- •Taking a closer look at our oncology business in slide five, oncology revenue increased 30% to $190 million, and oncology volumes grew 38% to approximately 79,000 tests in the Q4.
- •Together, these drivers will continue to catalyze very strong growth in our oncology business.
- •Reveal continues to be our fastest-growing product, reflecting growing demand for tissue-free MRD.
- •Turning to slide 9 to take a closer look at our Reveal data pipeline.
- •Shifting gears to our biopharma and data business in slide 11, we delivered another year of strong performance, with revenue growing 18% year-over-year to $210 million in 2025.
- •We are a leader in companion diagnostics, with 25 approvals to date across the U.S., Japan, and Europe, and a robust pipeline of ongoing CDx programs.
- •We delivered $35 million of Shield testing revenue in Q4, driven by approximately 38,000 tests, which was a meaningful step-up compared to 24,000 tests in Q3.
SourcesCompany financials · earnings call
Last updated